Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
India may issue a warning over cough syrup exported by Marion Biotech linked to a death in Uzbekistan.
Read Full NewsTelemedicine use is not associated with a substantial increase in mental health treatment among patients in rural, low-access, or distant communities, a new study shows.
A new analysis explores whether accelerating RT delivery with 6 fractions vs 5 fractions per week improves outcomes in patients with locally advanced HNSCC receiving concurrent chemotherapy.
Researchers have created nanoparticles that can remove disease-driving proteins while also delivering a chemotherapeutic or immunotherapeutic payload to cancer cells.
A population-based cohort study finds that an increased use of adjuvant systemic therapy can improve survival in patients with metachronous and synchronous bilateral breast cancer.
1.
Cancer Warnings on Alcohol? Surge in GI Illnesses; Swab Detects Kids' Asthma Type
2.
GLP-1 receptor agonists, cancer risk and questionable significance
3.
In early dementia, SSRIs enhance cognition and major depression.
4.
Global warming could be driving up women's cancer risk, find researchers
5.
Formaldehyde releasers found in common personal care products used especially by Black and Latina women
1.
Hepatocellular Carcinoma: Emerging Trends and Innovations in Diagnosis and Management
2.
Beyond the Standard: Personalized Cancer Vaccines and the Dawn of a New Era in Pediatric Oncology
3.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
4.
The Benefits and Risks of Cervical Conization
5.
Tailoring the Immune Response: The Dawn of Personalized Vaccines in Cancer Immunotherapy
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part IV
2.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
3.
Post Progression Approaches After First-line Third-Generaion ALK Inhibitors
4.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
5.
Updates on Standard V/S High Risk Myeloma Treatment
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge